National multicenter cohort of molar pregnancy in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter observational cohort that enrolls patients diagnosed with hydatidiform mole and collects complete clinical and pathological records. Participants are followed with serial serum hCG monitoring after uterine evacuation for at least six months, or until a diagnosis of postmolar gestational trophoblastic neoplasia (pGTN) if it occurs. The study aims to measure malignant transformation rates and to characterize mechanisms and risk factors underlying progression. Findings will be used to develop and promote more precise diagnosis and management pathways for molar pregnancy across China.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Clinically or pathologically diagnosed as hydatidiform mole.
2. Availability of complete medical records, including clinical and pathological data.
3. No evidence of myometrial invasion or metastasis.
4. Serum hCG levels normalized after uterine evacuation with at least 6 months of follow-up, OR diagnosed with postmolar gestational trophoblastic neoplasia (pGTN) during follow-up.
5. No history of psychiatric disorders, serious infectious diseases, or immune system diseases (such as systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).
6. Willing to participate in this study and sign the relevant informed consent form.

Exclusion Criteria:

1. Missing clinical data.
2. Loss to follow-up: Do not return to participating hospital for follow-up visits after uterine evacuation, or could not be contacted for subsequent monitoring of hCG changes.
3. Concomitant malignancies or autoimmune deficiency disorders (e.g., systemic lupus erythematosus, myasthenia gravis, HIV infection, etc.).
4. As determined by the investigator, the presence of medical, psychological, social, occupational, or other conditions that would violate the study protocol or impair the subject's ability to provide informed consent.

Where it's running

• Gansu Province Maternal and Child Care Hospital
  Lanzhou, Gansu, China Recruiting
• Hainan women and children medical center
  Haikou, Hainan, China Recruiting
• Obstetrics & Gynecology Hospital of Fudan University
  Shanghai, Shanghai Municipality, China Recruiting
• Peking Union Medical College Hospital
  Beijing, China Recruiting
• Shenzhen Maternity & Child Healthcare Hospital
  Shenzhen, Guangdong, China Not yet recruiting
• Hebei Medical University Third Hospital
  Shijiazhuang, Hebei, China Not yet recruiting

Study contacts

• Study coordinator: Xin Lu, MD & PhD
• Email: xin_lu@fudan.edu.cn
• Phone: +86-021-33189900

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment options for hydatidiform mole with lung nodules

  This study is testing different treatment options for patients with hydatidiform mole and lung nodules to see which approach works best for getting their hormone levels back to normal.

  Recruiting Women's Hospital School Of Medicine Zhejiang University · Hangzhou, Zhejiang · NCT03785574

• National reference center for gestational trophoblastic disease in France

  This study is about a special center in France that helps women with gestational trophoblastic disease by providing treatment and support while allowing them to stay connected with their local doctors.

  Recruiting Hospices Civils de Lyon · Pierre-Bénite · NCT02892877

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.